This continues for 6 weeks, with reassessment at the midpoint
A phase I safety study in healthy adults confirmed that subcutaneous MOTS-c injections at doses up to 10 mg produced no serious adverse events, with a pharmacokinetic profile supporting once-daily or every-other-day dosing [3]
Tirzepatide is a sensitive peptide, and vigorous shaking can damage the molecules, potentially making the medication less effective
Every protocol is prescribed by a licensed provider, sourced exclusively from an FDA-registered 503A compounding pharmacy, and available via telehealth across Illinois or for pickup at our clinic
Muscles, Ligaments & Tendons Journal 9(3), 305313 (2019).
But this is exactly what you need to focus on first